The above two results showed that CtBP2 can inhibit the development of prostate cancer through the c-Myc signaling pathway, implying that CtBP2 may have potential as a promising therapeutic approach for the treatment of prostate cancer. The gene discussed is CTBP2; the disease is prostate carcinoma.